Who are INR101's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PHYTONADIONE, Warfarin or coumadin, Warfarin duration, Warfarin (Coumadin), Sodium warfarin, Standard dose oral anticoagulant.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/inr101.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

INR101 — Competitive Intelligence Brief

INR101 (INR101) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vitamin K antagonist. Area: Cardiovascular.

phase 3 Vitamin K antagonist VKORC1 Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

INR101 (INR101) — Yunhe Pharmaceutical (Tianjin) Co., Ltd. INR101 is an anticoagulant that works by inhibiting the synthesis of vitamin K-dependent clotting factors.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
INR101 TARGET	INR101	Yunhe Pharmaceutical (Tianjin) Co., Ltd	phase 3	Vitamin K antagonist	VKORC1
PHYTONADIONE	PHYTONADIONE		marketed	Vitamin K [EPC]	Vitamin K epoxide reductase complex subunit 1 (VKORC1)	1982-01-01
Warfarin or coumadin	Warfarin or coumadin	Ottawa Heart Institute Research Corporation	marketed	Vitamin K antagonist (oral anticoagulant)	Vitamin K epoxide reductase complex 1 (VKORC1)
Warfarin duration	Warfarin duration	British Thoracic Society	marketed	Vitamin K antagonist (anticoagulant)	Vitamin K epoxide reductase complex 1 (VKORC1)
Warfarin (Coumadin)	Warfarin (Coumadin)	University of Michigan	marketed	Vitamin K antagonist (oral anticoagulant)	Vitamin K epoxide reductase (VKORC1)
Sodium warfarin	Sodium warfarin	University of Padova	marketed	Vitamin K antagonist (coumarin anticoagulant)	Vitamin K epoxide reductase complex 1 (VKORC1)
Standard dose oral anticoagulant	Standard dose oral anticoagulant	Korea University Guro Hospital	marketed	Vitamin K antagonist (warfarin-type oral anticoagulant)	Vitamin K epoxide reductase complex 1 (VKORC1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vitamin K antagonist class)

Joon Bum Kim · 1 drug in this class
Population Health Research Institute · 1 drug in this class
US Department of Veterans Affairs · 1 drug in this class
University Hospital, Bonn · 1 drug in this class
University Hospital, Limoges · 1 drug in this class
Yunhe Pharmaceutical (Tianjin) Co., Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). INR101 — Competitive Intelligence Brief. https://druglandscape.com/ci/inr101. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab